drugset / Trial / NCT02013336

Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors

NCT02013336 ↗

Phase 1 Recruiting 30 enrolled South Plains Oncology Consortium
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 1 study of the combination of two drugs: MM-398 and Cyclophosphamide. The goal is to find the highest dose of MM-398 that can be given safely when it is used together with the chemotherapy drug Cyclophosphamide.

Timeline

Start
2013-12
Primary completion
2026-12
Completion
2027-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Irinotecan Sucrosofate Other / unclassified — —
Background Cyclophosphamide Other / unclassified — Intravenous